BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 34632695)

  • 1. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV.
    Tuan JJ; Zapata H; Critch-Gilfillan T; Ryall L; Turcotte B; Mutic S; Andrews L; Roh ME; Friedland G; Barakat L; Ogbuagu O
    HIV Med; 2022 Feb; 23(2):178-185. PubMed ID: 34632695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH).
    Tuan JJ; Zapata H; Barakat L; Andrews L; Behnegar A; Kim YW; Kayani J; Mutic S; Ryall L; Turcotte B; Critch-Gilfillan T; Zhao M; Salahuddin S; Gupta S; Sutton R; Friedland G; Emu B; Ogbuagu O
    BMC Infect Dis; 2022 Sep; 22(1):744. PubMed ID: 36131232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
    PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH: A monocentric study in Bari, Italy.
    Milano E; Ricciardi A; Casciaro R; Pallara E; De Vita E; Bavaro DF; Larocca AMV; Stefanizzi P; Tafuri S; Saracino A
    J Med Virol; 2022 May; 94(5):2230-2236. PubMed ID: 35106771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
    Corma-Gómez A; Fernández-Fuertes M; García E; Fuentes-López A; Gómez-Ayerbe C; Rivero-Juárez A; Domínguez C; Santos M; Viñuela L; Palacios R; Real LM; Rivero A; Macías J; Pineda JA; García F
    Clin Microbiol Infect; 2022 Nov; 28(11):1492-1498. PubMed ID: 35640840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.
    Datwani S; Kalikawe R; Waterworth R; Mwimanzi FM; Liang R; Sang Y; Lapointe HR; Cheung PK; Omondi FH; Duncan MC; Barad E; Speckmaier S; Moran-Garcia N; DeMarco ML; Hedgcock M; Costiniuk CT; Hull M; Harris M; Romney MG; Montaner JSG; Brumme ZL; Brockman MA
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV.
    Liu WD; Pang MW; Wang JT; Sun HY; Huang YS; Lin KY; Wu UI; Li GC; Liu WC; Su YC; He PC; Lin CY; Yeh CY; Cheng YC; Yao Y; Chen YT; Wu PY; Chen LY; Luo YZ; Chang HY; Sheng WH; Hsieh SM; Chang SY; Hung CC; Chang SC
    J Virus Erad; 2022 Dec; 8(4):100308. PubMed ID: 36531082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
    Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
    Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1.
    Levy I; Wieder-Finesod A; Litchevsky V; Biber A; Indenbaum V; Olmer L; Huppert A; Mor O; Goldstein M; Levin EG; Hod T; Cohen C; Lustig Y; Rahav G
    Clin Microbiol Infect; 2021 Dec; 27(12):1851-1855. PubMed ID: 34438069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study.
    Santos-Araújo C; Mota Veiga P; Santos MJ; Santos L; Romãozinho C; Silva M; Lucas C; Duarte ML; Haarhaus M; Haase M; Macário F
    Nephrol Dial Transplant; 2022 Jan; 37(2):375-381. PubMed ID: 34634116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment.
    Buttiron Webber T; Provinciali N; Musso M; Ugolini M; Boitano M; Clavarezza M; D'Amico M; Defferrari C; Gozza A; Briata IM; Magnani M; Paciolla F; Menghini N; Marcenaro E; De Palma R; Sacchi N; Innocenti L; Siri G; D'Ecclesiis O; Cevasco I; Gandini S; DeCensi A
    Eur J Cancer; 2021 Dec; 159():105-112. PubMed ID: 34742157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers.
    Heyming TW; Nugent D; Tongol A; Knudsen-Robbins C; Hoang J; Schomberg J; Bacon K; Lara B; Sanger T
    Int J Infect Dis; 2021 Dec; 113():1-6. PubMed ID: 34601142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
    Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.